A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Humacyte, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 264,300 shares of HUMA stock, worth $1.53 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
264,300
Holding current value
$1.53 Million
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.87 - $9.1 $758,541 - $2.41 Million
264,300 New
264,300 $1.27 Million
Q4 2023

Feb 14, 2024

BUY
$1.99 - $3.12 $101,888 - $159,744
51,200 New
51,200 $145,000

Others Institutions Holding HUMA

About Humacyte, Inc.


  • Ticker HUMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,007,000
  • Market Cap $595M
  • Description
  • Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...
More about HUMA
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.